Mode
Text Size
Log in / Sign up
N/A N=24 Randomized Double-blind Treatment

Erector Spinae Plane Blocks for Adolescent Idiopathic Scoliosis

Pain, Postoperative · Opioid Use · Recruitment

Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: Number of Patients Who Receive Bilateral, Pre-incision ESPB — 9; 12 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Bilateral Erector Spinae Plane Block with bupivacaine and dexamethasone (Procedure); No bilateral Erector Spinae Plane Block (no bupivacaine and no dexamethasone) (Other)
Age
Pediatric, Adult · 10+ yrs
Sex
All
Sponsor
Hospital for Special Surgery, New York
Primary completion
Nov 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients Who Receive Bilateral, Pre-incision ESPB
9; 12
SECONDARY
Rate of Recruitment
12; 12
SECONDARY
Blinding Assessment
0; -0.33
SECONDARY
Number of Participants Unable to Receive ESPB Block.
2; 0
SECONDARY
Attrition
3; 0
SECONDARY
Incidence of Intra- and Postoperative Complications Attributed to ESPB
0; 0
SECONDARY
Pain Scores at Rest and Movement
3.64; 3.58; 4; 2.5; 3.3; 3
SECONDARY
Total Opioid Consumption
78.23; 53.89
SECONDARY
Time to First Opioid Use
178; 94
SECONDARY
Opioid Related Side Effects
3; 9; 6; 7; 1; 2
SECONDARY
Patient/Parent Satisfaction With Pain Management
10; 8; 10; 9

Summary

Pediatric spinal fusion (PSF) surgery is a painful procedure that can treat adolescent idiopathic scoliosis (AIS). One technique that can potentially reduce patients' pain levels and need for opioid medication is the ultrasound-guided Erector Spinae Plane Block (ESPB). The ESP block is a technique that involves injecting an anesthetic medication into the muscles of the lower back on both sides of the spine. Previous studies have shown that ESPB application led to a reduction in opioid use, and there is one pediatric case report of ESPB use in two patients undergoing PSF. However, there is still lack of evidence that the ESPB technique is feasible and effective in the pediatric patient population. The present study is designed to be the first randomized controlled trial to evaluate the role of ESPB in pediatric spinal fusion surgery and the role of ESPB within an enhanced recovery pathway.

Eligibility Criteria

Inclusion Criteria

  • Age 10-19 years old
  • Patients undergoing multilevel posterior spinal instrumentation and fusion
  • Undergoing surgery for correction of adolescent idiopathic scoliosis
  • Patients under the care of participating surgeons
  • English Speaking

Exclusion Criteria

  • Patients younger than 10 years old or older than 19 years old
  • Neuromuscular scoliosis
  • Patient under the care of non-participating surgeon performing the procedure
  • History of chronic opioid therapy (longer than 4 weeks) to treat back pain attributed to scoliosis tolerance, as defined by Centers for Disease Control (CDC) criteria (more than 60 oral morphine equivalents (OME) daily for over 2 weeks)
  • Chronic pain conditions necessitating neuromodulating medications (gabapentin, pregabalin)
  • Allergy, intolerance, or contraindication to any protocol component/study medication/technique
  • Patient or parent refusal
  • Non-english speaking
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04500613). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search